CD8A and acute lymphoblastic leukemia: Moreover, in a phase I trial of children and young adult with relapsed or refractory B-lineage ALL, Gardner and colleagues, using a CAR T cell products with a defined CD4/CD8 composition, observed a very impressive remission rates and prolonged overall survival (28).